Partnering With Innovators to Treat Serious Illness

Partnering With Innovators
to Treat Serious Illness
A
mgen Business Development seeks smart, strategic deals that leverage technologies and capabilities to deliver even better outcomes for patients than we could on our own. We’re focused on medicines that treat
serious illnesses and address large unmet medical needs as we strive to reach more patients in more countries
around the world.
For more information visit www.amgenbd.com
Amgen’s Business Development Team
Dave Piacquad
Senior Vice President
Business Development
[email protected]
William Erb
Vice President
Business Development
[email protected]
Bethany Mancilla
Vice President
Business Development
[email protected]
Ray Barlow, Ph.D.
Executive Director
Transactions
Europe/Russia
[email protected]
Jessica Droge, Ph.D.
Executive Director
External R&D
[email protected]
Jeremy Grunstein, Ph.D.
Executive Director
Technology/Outlicensing
[email protected]
Syed Kazmi, Ph.D.
Executive Director
Transactions
[email protected]
Rachna Khosla
Executive Director
Transactions
[email protected]
Janis Naeve, Ph.D.
Managing Director
Amgen Ventures
[email protected]
Georg Buchner, Ph.D.
Director
Business Development
Europe
[email protected]
Chris DeRespino
Director
Transactions
[email protected]
Helen Kim, Ph.D.
Director
Technology
[email protected]
Nkem Ogbechie
Director
Transactions
[email protected]
Alex Rabiee
Director
Technology/Outlicensing
[email protected]
Alex Turner Jr., Ph.D.
Director
Bone/Nephrology/
Neuroscience
[email protected]
Madhuri Borde
Senior Manager
Business Intelligence
[email protected]
Joyce Chan, Ph.D.
Senior Manager
Cardiometabolic
[email protected]
Andy Choo, Ph.D.
Senior Manager
Oncology
[email protected]
Christian Hein, MS
Senior Manager
Transactions
Europe/Russia
[email protected]
Gladys Nunez, MS
Principal
Amgen Ventures
[email protected]
Samantha Palmer, Ph.D.
Senior Manager
Inflammation
[email protected]
Thaminda Ramanayake
Senior Manager
Transactions
[email protected]
Chester Wong
Senior Manager
Business Intelligence
[email protected]
Martha Zambrano
Senior Manager
Technology
[email protected]
Ken Jung, MS
Manager
Technology
[email protected]
World-Class Capabilities
Therapeutic Areas
Fully integrated biotechnology organization
Oncology /Hematology
From human genetics and target validation to discovery and development to reaching patients globally,
Amgen can leverage innovation at virtually every stage in the process of getting a medicine to market.
“Biology First” advantage
Amgen’s approach to drug discovery starts with seeking to understand the fundamental mechanisms of
a disease and then using our expertise across multiple modalities to develop the appropriate protein,
antibody, small molecule, peptide or other modality necessary to hit a disease target. This agnostic
approach—and deep internal knowledge of how diseases work—makes Amgen positioned to see the
value of innovations from potential partners.
Cardiovascular Disease
Investing in external innovation
Roughly 50 percent of Amgen’s late-stage pipeline comes from external innovation—proof that we are
willing to invest in innovations to make a meaningful difference for patients, regardless of their origin.
Unique strength in protein engineering
Modifying protein structures to optimize a biologic medicine is a complex process. Amgen has industryleading expertise in this area to potentially improve innovations conceived both inside and outside the
company.
Inflammation
Global clinical trial experience
Amgen has extensive experience in conducting large-scale clinical trials—which have included nearly
30,000 patients and 20 trials for a single investigational medicine.
Leading biologics manufacturing capability
With more than three decades of experience and a record of reliably supplying medicines to patients,
Amgen is recognized worldwide as a leader in manufacturing complex biologic therapies.
Bone Health
Successful launch track record
Amgen has extensive experience launching products into existing therapeutic areas—and new ones.
Commercial infrastructure to bring medicines to market globally
Once Amgen medicines have been approved, we have the potential to bring them to patients on a global
scale with a presence in more than 100 countries.
Nephrology
Technology
Drug discovery platforms (e.g.,
multispan membrane proteins)
Molecules to enable druggable
proteins
Next-generation modalities
Conjugation and protein
engineering
Patient stratification and
predictive biomarkers
Protein/peptide formulation
technologies and delivery
devices
Companion diagnostics
- Aid in delivery of high-
concentration/low-volume doses
- Increase solubility and stability
- Enhance circulating half-life
- Alternative routes of administration
Proprietary research tools and
tissue access
Imaging platforms (e.g., nuclear
and substrate-free)
Gene-editing technologies
Immunotherapy platforms
Manufacturing (purification, viral
control and minimize cold chain
storage)
Neuroscience
A venture capital success story
Founded in 1980 by a small group of enterprising venture capitalists and scientists who saw the promise of emerging research in genetics, Amgen has grown
to be one of the world’s largest independent biotechnology companies with a rich late-stage pipeline, more than a dozen marketed products, approximately $19
billion in revenue and a presence in more than 75 countries.
Continuing tradition of partnership
At Amgen, Business Development remains a critical capability. We recognize that one of the most important drivers of success is our balanced approach of
capturing internal and external innovation. We have invested in more than 25 early-stage biotechnology companies in the last decade. These investments,
along with the work we have done at Amgen, have led to significant advances in the treatment of cancer, rheumatoid arthritis, kidney disease and other serious
illnesses. Our success continues to come from cultivating home-grown innovation inside the walls of Amgen while also capturing external innovation and
forging valuable partnerships that dramatically enhance how we deliver for patients.
Flexible and innovative deal structuring
We work with partners in a variety of ways to make the most of innovations that could deliver tangible benefits to those suffering from serious illness.
Recent transactions include spin-outs, limited partnership investments, equity investments, collaborations, joint ventures, in- and out-licensing, early-stage
partnerships and acquisitions.
Select deals and partnerships
Spin-Outs and Start-Ups
Atara, Celimmune, Flexus, Kezar Life Sciences , NextCODE, Relypsa
Equity Investments
Acerta, Adheron, Ardelyx IPO, Atara IPO, Epizyme IPO, Imago BioSciences, miRagen, Opsona, Precision Biosciences, Ra Pharma, Surface Oncology, Sutro,
Tizona, Ziarco
Joint Ventures
Amgen Astellas BioPharma, Amgen Betta Pharmaceuticals
Early-Stage Partnerships
Dako, Illumina, Massachusetts General Hospital (MGH) and the Broad Institute, Tetragenetics, Transgenomic, ShanghaiTech
Limited Partnership Investments
Atlas Fund IX, Decheng (Bay City), Orbimed Israel, Redmile Group, Rothschild, venBio
Collaborations
AstraZeneca, Cytokinetics, Dr. Reddy’s, Kite, Merck, Nantworks, Novartis, Roche, Servier, Teijin, Xencor
Acquisitions
deCODE, Bergamo, BioVex, Dezima, KAI, Micromet, Mustafa Nevzat, Onyx
For more information visit www.amgenbd.com
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799
www.amgen.com
©2016 Amgen Inc. All rights reserved. June 2016